Indy Hematology Review
J

DEBATE: Why Not to Transplant When MRD Has Been Achieved After Initial Therapy for MM

By Indy Hematology Review FEATURING Joseph Mikhael
By Indy Hematology Review FEATURING Joseph Mikhael
536 views
April 19, 2023
2 Comments
Login to view comments. Click here to Login

Featured Video

37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Related Content

AUTOPLAY
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
17:52
Indy Hematology Review

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Feat. K. Anderson
16:42
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of Myeloma - Highlights & Key T…

Feat. H. Hashmi
24:35
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 …

Feat. H. Hashmi
17:46
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Highlights in 1L MM - Quadruplet Therapies …

Feat. A. Jakubowiak
31:53
Indy Hematology Review

HSCT in 2024: What Every Hematologist Needs to Know

Feat. R. Childs
07:11
GRACE

CAR T-Cell vs. Bispecific Therapies for Blood Cancers: How Oncologis…

Feat. A. Goodman, A. Jeong, S. Rajeeve
19:08
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGU…

Feat. R. Banerjee
09:51
i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje
24:23
MyCancerHaven

Will CAR-Ts and Bispecifics Will Replace HSCT in Myeloma?

Feat. R. Vij, S. Al Hadidi
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
13:15
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Quadruplets in NDMM - The More the Better?…

Feat. O. Landgren
36:10
Insights from 2024 EHA Annual Meeting

Highlights in Plasma Cell Disorders From ASCO® and EHA

Feat. S. Al Hadidi
28:20
Indy Hematology Review

Managing Newly Diagnosed MM in 2024

Feat. S. Usmani
35:27
Dana-Farber Cancer Institute

Advances in Multiple Myeloma 2024: From Bench to Bedside

Feat. K. Anderson
19:24
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Updates on Managing Newly Diagnosed MM - In…

Feat. P. Richardson
13:47
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "MRD2STOP Study - Discontinuation of Maint…

Feat. B. Derman
06:19
Insights from 2023 ASH Annual Meeting

Dara-KRd in NDMM Without ASCT: Final Analysis of a Ph2 Trial

Feat. B. Derman
20:23
SOHO Brazil 2024

When to Consider Bispecific and CAR-T Therapy in MM

Feat. N. S. Raje
22:33
Integrity CE

Treatment Strategies for R/R MM After Frontline Anti-CD38 Therapy

Feat. S. Usmani, J. Hillengass